U.S. markets closed

SQZ Biotechnologies Company (SQZ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
13.55+0.30 (+2.26%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close13.25
Open13.26
Bid13.41 x 900
Ask13.46 x 900
Day's Range12.17 - 13.68
52 Week Range12.07 - 36.49
Volume257,959
Avg. Volume168,836
Market Cap336.451M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference
      Business Wire

      SQZ Biotech to Present at H.C. Wainwright Global Life Sciences Conference

      SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief executive officer of SQZ™, will present a corporate overview at the upcoming virtual H.C. Wainwright Global Life Sciences Conference. The presentation will be available through the virtual conference portal on Tuesday, March 9, 2021 at 7:00 am EST. The team is also taking individual meetings at the event.

    • Why SQZ Biotechnologies Sank on Friday
      Motley Fool

      Why SQZ Biotechnologies Sank on Friday

      SQZ Biotechnologies (NYSE: SQZ) fell by nearly 16% on Friday following the company's announcement of a new funding round. SQZ (pronounced "squeeze") is issuing 3 million new shares of common stock in an underwritten public offering that was priced Friday at $20 per share. As is customary in secondary stock flotations, SQZ's underwriters have been granted a 30-day option to purchase extra stock.

    • Benzinga

      SQZ Biotechnologies Under Pressure After $60M Equity Raise At 9% Discount

      SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares. The offer price represents a discount of 9% on the last close of $22 on Thursday. The offering is expected to close on February 17. BofA Securities, Evercore ISI, and Stifel are acting as joint book-running managers for the offering. BTIG is acting as the lead manager for the offering. The FDA recently signed off the company's Investigational New Drug application for SQZ Activating Antigen Carriers in HPV+ tumors. The trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells engineered with tumor-specific antigens. This trial marks the first clinical program from the company's SQZ AAC platform. Price Action: SQZ stock dropped 17.7% at $18.12 in the market trading hours on the last check Friday. See more from BenzingaClick here for options trades from BenzingaCorvus Pharma Shares Drop After M Equity Raise At 11% DiscountOncorus Secures M Via Equity At 9% Discount© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.